FDA Responds to Patient Advocacy on RP1 + Nivolumab
As part of our continued advocacy for patients with advanced melanoma, we are sharing the U.S. Food and Drug Administration’s…
Blog - Melanoma360
02/05/2026
FDA Responds to Patient Advocacy on RP1 + Nivolumab
As part of our continued advocacy for patients with advanced melanoma, we are sharing the U.S. Food and Drug Administration’s…
|
02/05/2026
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate SAN CARLOS, Calif., Feb.…
|
|
01/23/2026
Moderna, Merck’s Skin Cancer Vaccine Shows Sustained Benefit in Five-Year Follow-Up
By Kamal Choudhury and Mariam E SunnyJanuary 20, 2026 3:52 PM EST Jan 20 (Reuters) – Moderna (MRNA.O), opens new tab and Merck…
|
01/21/2026
Reflecting on Melanoma Treatment in 2025 and Looking to the Future in 2026
The start of a new year is a time for reflection and looking to the future. This is an ideal…
|
01/13/2026
The Integrative Care Approach
Guest: Lisa Simms Booth, Executive Director, Smith Center for Healing and the Arts In this episode of the Beyond the…
|
01/13/2026
Improved Response to Immunotherapy with COVID-19 mRNA Vaccines
Introduction Data from a new study presented at the European Society for Medical Oncology (ESMO) meeting and published in Nature…
|
12/09/2025
One Day at a Time: Caregiving Through Ocular Melanoma
In this episode, we sit down with Vanessa Tompkins, wife and caregiver to Mike, who has been battling Stage IV…
|
11/24/2025
A Life Rewritten: Finding Strength in the Face of Melanoma
By Mara Klecker Just Normal People Asked to describe his life before the first melanoma diagnosis—before losing an eye, undergoing…
|
11/20/2025
Living Through TIL Therapy: A Personal Story
By Mara Klecker Michael Moran shared his personal journey with melanoma to inspire, educate, and support others affected by this…
|
11/07/2025
You’re Not Out of Options: What to Do When First-Line Melanoma Treatment Fails
Melanoma treatment has advanced dramatically over the past decade, with immunotherapy and targeted therapies offering hope for many patients. However,…
|
Recent Posts
Apr. 27, 2026
Lilly Pulitzer and AIM at Melanoma Partner for 5th Annual Community Giving Event
Apr. 19, 2026
KIMMTRAK doubles the likelihood of being alive at five years for firstline HLA-A*02:01+ patients with metastatic uveal melanoma
Apr. 10, 2026
FDA Does Not Approve RP1 in Combination with Nivolumab for Advanced Melanoma: What This Means for Patients
Apr. 07, 2026
2026 National Sunscreen Partner
Apr. 07, 2026